Literature DB >> 31301335

AMP-activated protein kinase slows D2 dopamine autoreceptor desensitization in substantia nigra neurons.

Wei Yang1, Adam C Munhall2, Steven W Johnson3.   

Abstract

Dopamine neurons in the substantia nigra zona compacta (SNC) are well known to express D2 receptors. When dopamine is released from somatodendritic sites, activation of D2 autoreceptors suppresses dopamine neuronal activity through activation of G protein-coupled K+ channels. AMP-activated protein kinase (AMPK) is a master enzyme that acts in somatic tissues to suppress energy expenditure and encourage energy production. We hypothesize that AMPK may also conserve energy in central neurons by reducing desensitization of D2 autoreceptors. We used whole-cell patch-clamp recordings to study the effects of AMPK activators and inhibitors on D2 autoreceptor-mediated current in SNC neurons in midbrain slices from rat pups (11-23 days post-natal). Slices were superfused with 100 μM dopamine or 30 μM quinpirole for 25 min, which evoked outward currents that decayed slowly over time. Although the AMPK activators A769662 and ZLN024 significantly slowed rundown of dopamine-evoked current, slowing of quinpirole-evoked current required the presence of a D1-like agonist (SKF38393). Moreover, the D1-like agonist also slowed the rundown of quinpirole-induced current even in the absence of an AMPK activator. Pharmacological antagonist experiments showed that the D1-like agonist effect required activation of either protein kinase A (PKA) or exchange protein directly activated by cAMP 2 (Epac2) pathways. In contrast, the effect of AMPK on rundown of current evoked by quinpirole plus SKF38393 required PKA but not Epac2. We conclude that AMPK slows D2 autoreceptor desensitization by augmenting the effect of D1-like receptors.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  AMP kinase; D1 receptor; D2 autoreceptor; Desensitization; Dopamine; Substantia nigra

Mesh:

Substances:

Year:  2019        PMID: 31301335      PMCID: PMC6745265          DOI: 10.1016/j.neuropharm.2019.107705

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  82 in total

Review 1.  Structure, function, and control of phosphoinositide-specific phospholipase C.

Authors:  M J Rebecchi; S N Pentyala
Journal:  Physiol Rev       Date:  2000-10       Impact factor: 37.312

Review 2.  Bioenergy sensing in the brain: the role of AMP-activated protein kinase in neuronal metabolism, development and neurological diseases.

Authors:  Stephen Amato; Heng-Ye Man
Journal:  Cell Cycle       Date:  2011-10-15       Impact factor: 4.534

3.  Characterization of the AMP-activated protein kinase kinase from rat liver and identification of threonine 172 as the major site at which it phosphorylates AMP-activated protein kinase.

Authors:  S A Hawley; M Davison; A Woods; S P Davies; R K Beri; D Carling; D G Hardie
Journal:  J Biol Chem       Date:  1996-11-01       Impact factor: 5.157

4.  Inhibition by MK-801 of morphine-induced conditioned place preference and postsynaptic dopamine receptor supersensitivity in mice.

Authors:  H S Kim; C G Jang; W K Park
Journal:  Pharmacol Biochem Behav       Date:  1996-09       Impact factor: 3.533

5.  Trace amines depress D(2)-autoreceptor-mediated responses on midbrain dopaminergic cells.

Authors:  Ada Ledonne; Mauro Federici; Michela Giustizieri; Mauro Pessia; Paola Imbrici; Mark J Millan; Giorgio Bernardi; Nicola B Mercuri
Journal:  Br J Pharmacol       Date:  2010-07       Impact factor: 8.739

Review 6.  Regulation of ion channels and transporters by AMP-activated kinase (AMPK).

Authors:  Florian Lang; Michael Föller
Journal:  Channels (Austin)       Date:  2013-12-23       Impact factor: 2.581

7.  AMP kinase regulates ligand-gated K-ATP channels in substantia nigra dopamine neurons.

Authors:  Ke-Zhong Shen; Yan-Na Wu; Adam C Munhall; Steven W Johnson
Journal:  Neuroscience       Date:  2016-06-05       Impact factor: 3.590

8.  Phenotypical characterization of the rat striatal neurons expressing the D1 dopamine receptor gene.

Authors:  C Le Moine; E Normand; B Bloch
Journal:  Proc Natl Acad Sci U S A       Date:  1991-05-15       Impact factor: 11.205

9.  Latrepirdine is a potent activator of AMP-activated protein kinase and reduces neuronal excitability.

Authors:  P Weisová; S P Alvarez; S M Kilbride; U Anilkumar; B Baumann; J Jordán; T Bernas; H J Huber; H Düssmann; J H M Prehn
Journal:  Transl Psychiatry       Date:  2013-10-22       Impact factor: 6.222

10.  Cav1.3 channels control D2-autoreceptor responses via NCS-1 in substantia nigra dopamine neurons.

Authors:  Elena Dragicevic; Christina Poetschke; Johanna Duda; Falk Schlaudraff; Stephan Lammel; Julia Schiemann; Michael Fauler; Andrea Hetzel; Masahiko Watanabe; Rafael Lujan; Robert C Malenka; Joerg Striessnig; Birgit Liss
Journal:  Brain       Date:  2014-06-16       Impact factor: 13.501

View more
  3 in total

Review 1.  Dopamine D2 autoreceptor interactome: Targeting the receptor complex as a strategy for treatment of substance use disorder.

Authors:  Rong Chen; Mark J Ferris; Shiyu Wang
Journal:  Pharmacol Ther       Date:  2020-05-27       Impact factor: 12.310

2.  Dopamine Evokes a Trace Amine Receptor-dependent Inward Current that is Regulated by AMP Kinase in Substantia Nigra Dopamine Neurons.

Authors:  Wei Yang; Adam C Munhall; Steven W Johnson
Journal:  Neuroscience       Date:  2019-12-26       Impact factor: 3.590

3.  Effects of Chemogenetic Inhibition of D1 or D2 Receptor-Containing Neurons of the Substantia Nigra and Striatum in Mice With Tourette Syndrome.

Authors:  Lixue Lin; Yuye Lan; He Zhu; Lingling Yu; Shuang Wu; Wangyixuan Wan; Yang Shu; Hongchun Xiang; Tengfei Hou; Hong Zhang; Yan Ma; Wen Su; Man Li
Journal:  Front Mol Neurosci       Date:  2021-12-09       Impact factor: 5.639

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.